Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $20.52

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares gapped up before the market opened on Wednesday . The stock had previously closed at $20.52, but opened at $21.26. Taysha Gene Therapies shares last traded at $21.00, with a volume of 14 shares trading hands.

Several brokerages recently weighed in on TSHA. William Blair began coverage on Taysha Gene Therapies in a research note on Monday, March 1st. They issued an “outperform” rating and a $46.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating on shares of Taysha Gene Therapies in a research note on Monday, April 26th. Zacks Investment Research downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, March 9th. Finally, Morgan Stanley boosted their target price on Taysha Gene Therapies from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, April 19th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Taysha Gene Therapies presently has a consensus rating of “Buy” and an average target price of $43.92.

The business has a fifty day moving average price of $22.38 and a 200-day moving average price of $24.46.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Tuesday, May 11th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.33). As a group, equities analysts predict that Taysha Gene Therapies, Inc. will post -3.19 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Wells Fargo & Company MN bought a new position in shares of Taysha Gene Therapies during the fourth quarter valued at $330,000. BlackRock Inc. lifted its holdings in Taysha Gene Therapies by 21.1% in the fourth quarter. BlackRock Inc. now owns 2,229,816 shares of the company’s stock valued at $59,181,000 after acquiring an additional 389,249 shares during the period. Citigroup Inc. purchased a new stake in Taysha Gene Therapies in the fourth quarter worth about $43,000. Bank of New York Mellon Corp purchased a new stake in Taysha Gene Therapies in the fourth quarter worth about $716,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth about $630,000. 42.19% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome.

Further Reading: What does an equal weight rating mean?

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.